Premium
A novel monoclonal antibody specifically reactive with human T‐lymphotropic virus type‐II (HTLV‐II) envelope protein
Author(s) -
Ohara Nobuya,
Hayashi Kazuhiko,
Takahashi Kiyoshi,
Miyamoto Kanji,
Akagi Tadaatsu
Publication year - 1993
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910540522
Subject(s) - monoclonal antibody , virology , microbiology and biotechnology , viral envelope , western blot , biology , antibody , virus , glycoprotein , epitope , human t lymphotropic virus , immunology , gene , biochemistry , neuroscience , myelopathy , spinal cord
A novel monoclonal antibody (MAb), N5.4.4, specifically reactive with human T‐lymphotropic virus type‐ll (HTLV‐II) envelope glycoprotein (gp) has been developed through immunization with a synthetic peptide corresponding to the amino acid sequence 171–196 of the HTLV‐II envelope protein (ll‐env 171–196). This MAb, which belonged to the IgG 1 kappa subclass, reacted with the cytosmears of HTLV‐ll‐infected cell lines (Si‐IIA, CR‐MA‐I and AS‐IIA), but not with those of HTLV‐1‐infected cell lines (MT‐1 and MT‐2) or other HTLV‐uninfected cell lines. On Western blot analysis, this MAb reacted with gp46 of HTLV‐II lysates but not with HTLV‐1 lysates. Moreover, flow‐cytometric analysis revealed that this MAb recognized the native surface of only the HTLV‐ll‐producing cells. Through application to immunohistochemical or serological method, this MAb may be of value in elucidating the pathogenesis of HTLV‐II infection in comparison with HTLV‐1.